FDA Approves Brain Penetrant Therapy for Gaucher Type 3

FDA approved venglustat, Infilbray, on November 18 for neurological symptoms of Gaucher type 3 in adults and children weighing at least 15 kg. This is the first FDA-approved therapy for that neurological manifestation, with…




